ARTICLE | Clinical News
Lilly stops AD trial of LY2886721
June 14, 2013 12:22 AM UTC
Eli Lilly and Co. (NYSE:LLY) discontinued the Phase II BACC trial evaluating once-daily oral LY2886721 for 26 weeks in patients with Alzheimer's disease (AD) after cases of abnormal liver biochemical ...